{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016489","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.478743+00:00","generated_at":"2026-06-24T01:35:25.821669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rani Therapeutics Q2 net loss $16M; positive RT-102 Phase 1 results","bullets":["Positive Phase 1 topline results for RT-102 (PTH capsule for osteoporosis): high bioavailability, well-tolerated, all endpoints met.","Completed debt financing up to $45M with Avenue Capital Group; $15M funded at closing; cash runway extended into mid-2024.","Cash and equivalents $97.2M at June 30, 2022 vs $117.5M at Dec 31, 2021.","Net loss of $16.0M in Q2 2022 vs $5.5M in Q2 2021; R&D expenses rose to $9.5M.","Near-term milestones: repeat-dose RT-102 results in Q4 2022, additional Phase 1 trial initiation in 2H 2022, pre-IND meeting with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016489","json":"https://secwatch.observer/filing/0000950170-22-016489.json","markdown":"https://secwatch.observer/filing/0000950170-22-016489.md","text":"https://secwatch.observer/filing/0000950170-22-016489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017022016489/0000950170-22-016489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017022016489/rani-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:35:25.821669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}